Background: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin-pegylated liposomal doxorubicin (PLD)] or CP (carboplatin-paclitaxel) in the CALYPSO trial.
introduction
In patients with recurrent ovarian cancer (ROC), response to further treatment at relapse and patient outcome are dependent on the length of treatment-free interval (TFI) between the end of previous chemotherapy and recurrence [1] . Current treatment guidelines recommend platinum combination therapy for patients with a TFI of >6 months and such therapy is standard in patients with a >12-month TFI [2] . However, no specific recommendations exist for patients with a TFI of 6-12 months, while evidence shows lower response rates to chemotherapy and unfavorable outcomes in these patients compared with those with a TFI of >12 months [1, 3] .
Pegylated liposomal doxorubicin (PLD) alone and in combination with carboplatin has shown favorable efficacy in platinum-sensitive ROC. Superiority of PLD monotherapy compared with topotecan was demonstrated for progressionfree survival (PFS) and overall survival (OS) [4, 5] . Notably, the survival benefit was more prominent for partially sensitive patients [hazard ratio (HR) of 1.58 versus 1.15 for those with a TFI >12 months] [5] . The combination of PLD and carboplatin was shown to be effective and well tolerated in late ROC by the Groupe d'Investigateurs Nationaux pour l'É tude des Cancers Ovariens (GINECO) in a phase II trial [6] . These results were confirmed by the same group in a prospective cohort [7] . Results for the whole cohort were an overall response rate of 65.4%, PFS of 13.6 months, and OS of 38.9 months. In the partially platinum-sensitive cohort, PFS was 9.8 months and OS was 30 months.
Based on these promising results, GINECO initiated a subsequent phase III trial, CALYPSO. This study was an international randomized Gynecologic Cancer Intergroup (GCIG) trial that evaluated the non-inferiority and safety of CD (carboplatin plus PLD) compared with CP (carboplatin plus paclitaxel) in patients with platinum-sensitive ROC, defined as relapse >6 months after first-or second-line therapy. The CALYPSO trial demonstrated that the CD regimen was superior to CP, with a more favorable therapeutic index for CD compared with CP [8] .
Among the stratifications at randomization in CALYPSO was the length of TFI, which categorized patients as having disease that was fully platinum-sensitive (>12 months TFI) or partially platinum-sensitive (>6 and £12 months TFI). In the current report, patients from CALYPSO who had partially platinumsensitive disease were analyzed separately for efficacy and safety outcomes.
patients and methods
The design and methods of CALYPSO were previously reported [8] . Briefly, CALYPSO was an international randomized, phase III, open-label multicenter trial that enrolled 976 patients with platinum-and taxanepretreated ovarian cancer that recurred >6 months after first-or secondline platinum-based chemotherapy. Patients were randomized to receive carboplatin (C) AUC 5 plus PLD 30 mg/m 2 (CD) on day 1 every 4 weeks or C AUC 5 plus paclitaxel (P) 175 mg/m 2 (CP) on day 1 every 3 weeks.
Treatment continued for six cycles or until disease progression or unacceptable toxicity. Additional chemotherapy cycles were permitted for patients achieving stable disease or response. Assessment for toxicity was performed prior to each cycle and tumor assessments were performed every 3 months while patients were on treatment. Assessments after treatment discontinuation consisted of CA-125 determination, clinical exam, and adverse event evaluation every 3 months for 2 years and every 6 months thereafter for 5 years.
All analyses, which were pre-planned, use the intent-to-treat population, which includes all randomized patients with a treatment-free interval of >6 and £12 months, excluding one patient who did not have ovarian cancer. CALYPSO was designed as a non-inferiority trial for which the primary end point was PFS designed to detect a non-inferiority margin of 19%. In the current analysis, PFS is assessed in the partially platinum-sensitive subset using the Kaplan-Meier method. The log-rank test is used to compare PFS between treatment arms and Cox proportional hazards model used to estimate the treatment effect. Wilcoxon rank sum test is used to compare all response categories (including unknown). Toxicities are compared using the chi-square test for independence of grade ‡3 across treatment groups; P-values are not adjusted for multiple comparisons across toxicities.
results
From April 2005 to September 2007, 344 partially platinum-sensitive patients were included in the CALYPSO trial, 161 in the CD arm and 183 in the CP arm, which is consistent with the whole CALYPSO population. Baseline characteristics were generally well balanced between treatment arms (Table 1) .
treatment administered
The median number of cycles delivered was 6 (range 1-12) in each arm. The ratio of delivered versus planned dose for each arm was 99% for C in both arms, 99% for PLD, and 97% for P. Median duration of treatment was longer in CD arm: 21 weeks versus 16 in CP arm, P < 0.001.
The proportion of patients completing at least six cycles was 81% in the CD arm and 77% in the CP arm. The percentage of patients completing nine cycles in the CD and CP arms was 8% and 9%, respectively, and the percentage Table 2) . Response rates were not statistically significantly different between arms (P = 0.691). At the time of the analysis, 191 patients (56%) were alive and overall survival data was immature.
safety All patients except three for whom data were missing were assessable for toxicity. The most common grade 3 or 4 hematologic toxicity, neutropenia, was more frequent in the CP arm (50%) compared with the CD arm (39%; P = 0.015) ( Table 3) . Grade 3 or 4 non-hematologic events were experienced by 57 patients (35%) on the CD arm and 73 patients (41%) on the CP arm (P = 0.366) ( Table 3 ). Grade 2 alopecia was much more frequent with CP versus CD (86% versus 9%; P < 0.001). Neuropathy and hypersensitivity reactions were also more frequent in the CP arm. Hand-foot syndrome (HFS) was more frequent in the CD arm but was mild to moderate in severity. Only one patient in each arm experienced grade 3-4 HFS. The proportion of patients experiencing any delayed toxicity or adverse event was greater with CP (42%) than with CD (23%; P < 0.001).
Three patients suffered fatal adverse events deemed possibly or likely related to study treatment. In the CD arm, one patient experienced cerebral hemorrhage and one patient developed acute myeloid leukemia, each thought to be possibly related to study drug. In the CP arm, one patient experienced acute pulmonary edema, thought to be related to a computed tomography scan.
discussion
In patients with partially platinum-sensitive recurrent ovarian cancer (TFI of 6-12 months), CALYPSO, which is the only study comparing platinum combinations in this indication, is the first trial to show a superior therapeutic index of an experimental platinum combination arm (CD) compared with the current standard (CP). This subset analysis of CALYPSO demonstrated that CD was not only non-inferior to CP with respect to PFS but was even found to be significantly superior. Carboplatin-PLD was associated with a 27% reduction in risk of recurrence (HR = 0.73; P = 0.004) compared with CP. These results reflect those of the whole intent-to-treat CALYPSO population, which included all patients with a TFI of >6 months [8] . In the whole CALYPSO population, CD was associated with an 18% reduction in risk of recurrence (HR = 0.82, 95% CI: 0.72-0.94; P = 0.005). Until today, CALYPSO is the only phase III trial comparing two platinum combination regimens in patients with platinum-sensitive ROC. Two previous trials compared a platinum combination (CP or carboplatin-gemcitabine) with single-agent platinum, and both could demonstrate superior efficacy of the combination regimen with risk reduction of recurrence of 24% and 28%, respectively [9, 10] . About one-third of the patients in both trials were partially platinum sensitive; and while the combination therapy with gemcitabine demonstrated a benefit, the addition of paclitaxel was not statistically superior in this subgroup. The combination of carboplatin with either paclitaxel or gemcitabine subsequently became the standard treatment for women relapsing >6 months after the completion of previous platinum-based chemotherapy.
More recently, a randomized trial of platinum-free therapy in patients with platinum-sensitive relapsed ovarian cancer was presented (OVA-301), comparing the combination of PLD and trabectedin with single-agent PLD [11] . This trial could also demonstrate a significant 21% reduction of the risk of recurrence for the combination arm. Of note, the subgroup of partially platinum-sensitive patients (32% of the overall population) in this trial has been analyzed separately, showing a 35% risk reduction of disease progression or death with a median PFS of 7.4 versus 5.5 months [12] . However, the OVA-301 trial met with criticism regarding the lack of platinum in the standard arm; as a consequence, we actually do not know how this combination compares with a platinum doublet and a large randomized intergroup trial is starting to compare these two options.
The improved efficacy of CD compared with CP observed in the current analysis of a patient population with unfavorable prognosis and early recurrence is remarkable. One possible explanation could be the increased susceptibility of recurrent tumor cells to a new drug (PLD) that was not applied during first-line therapy. The higher reduction in risk of recurrence observed in our population (27% versus 18% in the overall population) may suggest that the increased susceptibility to a modification of the compound combined to carboplatin is higher in this group. The trend we observed toward higher response for CP (45%) versus CD (39%) contradicts this hypothesis. However, the difference in response rate is not statistically significant. Though another explanation could be the difference in the length of treatment between the two arms, it has been proven that duration of treatment does not significantly improve results [13, 14] .
The life expectancy after first relapse is now longer than in the past, most patients may be on therapy for prolonged periods and ovarian cancer could be considered a chronic disease [15] . As a consequence, choosing a chemotherapy option for patients with ROC must include careful evaluation of toxicities in addition to efficacy.
This analysis demonstrated that, consistent with the overall CALYPSO analysis [8] , CD offers a favorable risk-benefit ratio compared with CP. CP was associated with more severe and long-term toxicity, including carboplatin hypersensitivity, alopecia and persistent sensory neuropathy. Nausea, vomiting and HFS were more common with CD. However, the rate of grade 3-4 HFS was very low in this population (1%), consistent with a phase II trial of this combination [16] . A lower rate of carboplatin-associated hypersensitivity reactions in the CD arm (0% versus 30%) is also confirmed in the final results of a randomized trial of CD versus carboplatin alone in platinum-sensitive ROC [17] . The authors hypothesized that this observation may relate to short-term effects of liposomes on immune cells responsible for platinum allergic reactions. They concluded that the enhancement of the opportunity to safely administer carboplatin may be as relevant as the delivery of the second antineoplastic drug itself.
In the AGO trial comparing the combination of carboplatin and gemcitabine with single-agent carboplatin in platinumsensitive disease (>6 months), the combination regimen was associated with better efficacy but higher hematologic toxicity [10] . The incidence of hematologic toxicity was lower in the CD arm of the current study (grade 3-4 neutropenia 39% versus 70.3%; grade 3-4 thrombocytopenia 15% versus 34.9%; grade 3-4 anemia 11% versus 27.4%). Furthermore, the administration of gemcitabine on days 1 and 8 every 3 weeks is more inconvenient than the administration of CD every 4 weeks.
In a phase II study of CD combination reporting efficacy stratified by platinum sensitivity (fully or partially), toxicity was globally evaluated [16] . Hematologic and non-hematologic toxicities were quite similar and even lower in the current study (grade 3-4 neutropenia 39% versus 55%; grade 3-4 thrombocytopenia 15% versus 42.5%; HFS 1% versus 7.5%; and the same rate of nausea, vomiting, and anemia). On the contrary, in another phase II study of CD combination in partially platinum-sensitive ROC, Power et al. [18] reported a better treatment tolerability than in the current study, but they underlined that none of their patients received two prior courses of chemotherapy.
When compared with single-agent PLD in the OVA-301 study [12] , the trabectedin/PLD combination induced a higher incidence of transient neutropenia and transaminase elevations and a lower incidence of HFS and mucositis. The rate of HFS and mucositis was similar with CD in the current study, while neutropenia was even lower (grade 3-4 neutropenia 39% versus 59.3%) and no liver toxicity was reported. Unlike platinumand taxane-based regimens, both CD and trabectedin/PLD combinations were associated with greatly diminished incidence of neuropathy and alopecia. The toxicity profile of CD remains favorable also when compared with this promising non-platinum combination.
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